Michael Polansky has a new, skin-focused biotech. Don’t call it a drug company.

Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious about steering clear of road bumps that slow biotechs.